A pilot clinical trial of the angiotensin-converting enzyme inhibitor ceranapril in Alzheimer disease

Alzheimer Dis Assoc Disord. 1993 Summer;7(2):105-11. doi: 10.1097/00002093-199307020-00006.

Abstract

This pilot clinical trial was a 15-week, double-blind, controlled, three-way crossover study evaluating cognitive effects of ceranapril in subjects with dementia of the Alzheimer type (age range 50-75 years). Computerized (CNTB) and noncomputerized cognitive test batteries revealed no significant results (p > 0.05). On further analysis of the data, however, a study of longer duration and/or higher dosages may be warranted.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Aged
  • Alzheimer Disease / drug therapy*
  • Alzheimer Disease / psychology
  • Angiotensin-Converting Enzyme Inhibitors / administration & dosage*
  • Angiotensin-Converting Enzyme Inhibitors / adverse effects
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Female
  • Humans
  • Male
  • Middle Aged
  • Neuropsychological Tests
  • Organophosphorus Compounds / administration & dosage*
  • Organophosphorus Compounds / adverse effects
  • Pilot Projects
  • Proline / administration & dosage
  • Proline / adverse effects
  • Proline / analogs & derivatives*

Substances

  • Angiotensin-Converting Enzyme Inhibitors
  • Organophosphorus Compounds
  • Proline
  • ceronapril